Decision Diagnostics EBIT per Share
EBIT per Share of Decision Diagnostics (DECN) as of Aug 10, 2026.
Get this data via API
Financial Data API
EBIT per Share
0.00USD
Last updated:
EBIT per Share of Decision Diagnostics is 2026 0.00 USD. EBIT per Share of Decision Diagnostics was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Decision Diagnostics Stock analysis
What does Decision Diagnostics do? The Decision Diagnostics Corp, founded in 2002, is a company specializing in the manufacturing of medical diagnostic test kits and devices. The company is headquartered in Westlake Village, California, and operates production facilities in various parts of the world.
The company's history began when the founders recognized a need for reliable, affordable, and easy-to-use diagnostic devices. This realization led to the development of the first product, the Shasta GenStrip. This test strip allowed patients to monitor their blood sugar levels at home, thereby better managing their diabetes.
Since then, Decision Diagnostics Corp has become a leading provider of diagnostic test kits and devices. The company has several divisions, including the pharmaceutical division, the medical division, and the consumables division.
In the pharmaceutical division, the company develops and produces tests for the pharmaceutical industry. These tests are used to assess the efficacy of new drugs and detect side effects.
The medical division, on the other hand, focuses on developing diagnostic devices for various applications. This includes a test for detecting cancer markers in the blood or a test for assessing vitamin D levels.
Another important division of the company is the consumables division. Here, the company provides test strips, syringes, needles, and other materials needed in medical practices and hospitals.
The business model of Decision Diagnostics Corp is based on the idea that every person has the right to reliable medical care. Therefore, the company is committed to developing diagnostic devices and test kits that are easy to use and affordable. This allows patients to independently monitor their condition at home and take quick action if necessary.
An example of this is the Shasta GenStrip, the first test strip developed by the company. This test strip allows patients to measure their blood sugar at home and better manage their diabetes. The Shasta GenStrip is compatible with common blood glucose meters and is significantly cheaper than comparable products.
Another product developed in the medical division is the eScreen. This device allows for quick and reliable testing of urine samples for drugs or alcohol. The eScreen is primarily used in occupational medicine to ensure that employees are not using drugs.
Overall, Decision Diagnostics Corp has become an important player in the medical industry. The company strives to provide patients with access to high-quality and affordable diagnostic devices and test kits. Through the constant development of innovative products, the company contributes to improving medical care worldwide. Decision Diagnostics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Decision Diagnostics stock
On Eulerpool you can find the complete historical development of EBIT per Share Decision Diagnostics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Decision Diagnostics
All Key Metrics — Decision Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth